Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324068 | 0.98 | CYP1A2 (0.39) | CYP1A2ALDH1A1NAAAEPHX1CHRNB2 | |
| SCHEMBL6331827 | 0.98 | CYP1A2 (0.37) | CYP1A2ALDH1A1NAAAEPHX1CHRNB2 | |
| SCHEMBL6325552 | 0.98 | CYP1A2 (0.39) | CYP1A2ALDH1A1NAAAEPHX1CHRNB2 | |
| SCHEMBL5459378 | 0.97 | CYP1A2 (0.37) | CYP1A2ALDH1A1EPHX1CHRNB2CHRNA7 | |
| SCHEMBL6323238 | 0.93 | CYP1A2 (0.42) | CYP1A2ALDH1A1 | |
| SCHEMBL6323627 | 0.92 | CYP1A2 (0.39) | CYP1A2ALDH1A1 | |
| SCHEMBL6325530 | 0.80 | CYP1A2 (0.48) | CYP1A2ALDH1A1EPHX1 | |
| SCHEMBL6332026 | 0.80 | CYP1A2 (0.48) | CYP1A2ALDH1A1EPHX1 | |
| SCHEMBL6324122 | 0.80 | CYP1A2 (0.48) | CYP1A2ALDH1A1EPHX1 | |
| SCHEMBL6330869 | 0.79 | FNTA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | CYP1A2 57/4885ALDH1A1 954/4885NAAA 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.